中华麻醉学杂志2024,Vol.44Issue(3) :260-266.DOI:10.3760/cma.j.cn131073.20231104.00302

乌司他丁对非体外循环冠状动脉旁路移植术患者术后肺部并发症的影响

Effect of ulinastatin on postoperative pulmonary complications in patients undergoing off-pump cor-onary artery bypass grafting

张召 耳建旭 翟文倩 任珉 郭志刚 韩建阁
中华麻醉学杂志2024,Vol.44Issue(3) :260-266.DOI:10.3760/cma.j.cn131073.20231104.00302

乌司他丁对非体外循环冠状动脉旁路移植术患者术后肺部并发症的影响

Effect of ulinastatin on postoperative pulmonary complications in patients undergoing off-pump cor-onary artery bypass grafting

张召 1耳建旭 1翟文倩 1任珉 2郭志刚 3韩建阁1
扫码查看

作者信息

  • 1. 天津市胸科医院麻醉科,天津 300222;天津市心血管急危重症重点实验室,天津 300222
  • 2. 天津市心血管病研究所,天津 300222
  • 3. 天津市心血管急危重症重点实验室,天津 300222;天津市胸科医院心血管外科,天津 300222
  • 折叠

摘要

目的 评价乌司他丁对非体外循环冠状动脉旁路移植术(OPCABG)患者术后肺部并发症(PPCs)的影响.方法 回顾性收集2021年9月至2023年8月择期行OPCABG患者的病历资料.根据患者术中是否使用乌司他丁分为乌司他丁组与对照组.通过倾向性评分匹配及扩展的Cox比例风险回归模型调整混杂因素.主要结局指标为术后30 d内PPCs发生情况,次要结局指标为ICU停留时间、住院时间及其他不良事件发生情况.结果 最终纳入1 532例患者,585例(38.2%)患者发生PPCs.与对照组比较,乌司他丁组PPCs发生率降低(匹配前:42.7%vs.35.2%,P=0.004;匹配后:42.2%vs.35.6%,P=0.033),急性肾损伤发生率降低,ICU停留时间、住院时间和其他不良事件发生率差异无统计学意义(P>0.05).在混杂因素调整前及调整后的Cox比例风险回归模型中,使用乌司他丁后PPCs发生风险降低(调整前HR=0.81,95%CI0.67~0.99,P=0.004;调整后HR=0.79,95%CI 0.65~0.96,P=0.022).年龄大于65岁、PPCs高风险患者使用乌司他丁后PPCs发生风险降低(HR=0.667,95%CI 0.542~0.821,P<0.001;HR=0.641,95%CI 0.516~0.812,P<0.001).结论 OPCABG患者术中使用乌司他丁有助于降低PPCs的发生风险.

Abstract

Objective To evaluate the effect of ulinastatin on the postoperative pulmonary compli-cations(PPCs)in the patients undergoing off-pump coronary artery bypass grafting(OPCABG).Methods Medical records from patients scheduled for elective OPCABG from September 2021 to August 2023 were retrospectively collected.The patients were divided into ulinastatin and control groups based on the intraop-erative use of ulinastatin.Confounding factors were adjusted using propensity score matching and an extend-ed Cox proportional hazards model.The primary outcome was the development of PPCs within 30 days after surgery,and secondary outcomes included length of stay in intensive care unit,length of hospital stay and occurrence of other adverse events.Results A total of 1 532 patients were included in this cohort study,and 585 cases(38.2%)experienced PPCs.Compared with control group,the incidence of PPCs was signif-icantly decreased(before matching:42.7%vs.35.2%,P=0.004;after matching:42.2%vs.35.6%,P=0.033),the incidence of acute kidney injury was decreased and no significant differences were found in the length of stay in intensive care unit,length of hospital stay and incidence of other adverse events in ulinasta-tin group(P>0.05).In the extended Cox proportional hazard model before and after adjustment for confoun-ding factors,the risk of PPCs was significantly reduced after the use of ulinastatin(HR value before adjust-ment was 0.81,95%confidence interval[CI]0.67-0.99,P=0.004;the HR value after adjustment was 0.79,95%CI 0.65-0.96,P=0.022).The risk of PPCs was significantly decreased in patients aged>65 yr and at high risk of PPCs after using ulinastatin(HR=0.667,95%CI 0.542-0.821,P<0.001;hR value was 0.641,95%CI 0.516-0.812,P<0.001).Conclusions The intraoperative use of ulinastatin is helpful in decreasing the risk of PPCs in patients undergoing OPCABG.

关键词

手术后并发症/胰蛋白酶抑制剂/冠状动脉旁路移植术,非体外循环

Key words

Postoperative complications/Trypsin inhibitors/Coronary artery bypass,off-pump

引用本文复制引用

基金项目

恩泽疼痛管理医学研究项目()

天津市卫生健康科技项目(TJWJ2023MS027)

天津市科技计划(20JCZDJC00810)

出版年

2024
中华麻醉学杂志
中华医学会

中华麻醉学杂志

CSTPCDCSCD北大核心
影响因子:1.235
ISSN:0254-1416
参考文献量26
段落导航相关论文